Lupin Limited · NSE:LUPIN
Lupin — Q1 FY27 Earnings Presentation
19 slides from Lupin's earnings presentation, Aug 7, 2026
Slide 1: Investor Presentation Q1 FY27
Investor Presentation Q1 FY27 August 07, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 3: Q1 FY27 Performance
Q1 FY27 Performance
Slide 4: Q1 FY27 - Key Growth Metrics
Q1 FY27 - Key Growth Metrics Continued Strong Operating Performance Key Metrics Business Performance Values in INR unless indicated otherwise 82,172 mn Sales India APAC 33% YoY 23,796 mn | 14% YoY 3,142 mn | Flat YoY LATAM 2,975 mn | 71% YoY 24,635 mn EBITDA1 30.0% North America 50% YoY Margin 35,90
Slide 5: Q1 FY27 - Key Developments
Q1 FY27 - Key Developments Strong Revenue Growth with Healthy EBITDA Margins Financials Key Launches / Approvals Sales* and EBITDA margin Trajectory Azilsartan Medoxomil Ranibizumab Launched US FDA Tabs In US (Ranluspec ) Approval 82,172 (RLD Edarbi®) biosimilar 73,919 80,000 37.0% 68,314 71,005 70,
Slide 6: Q1 FY27: Financial Snapshot
Q1 FY27: Financial Snapshot Sales Mix Key Financials INR mn Revenue (In INR mn and %) Q1 FY27 Q1 FY26 Q4 FY26 India, 23,796 29% United States, 34,3481 42% Sales 82,172 61,638 73,919 API, 2,637 3% EBITDA3 24,635 16,414 21,710 Emerging Markets2, 9,897 Other Developed 12% Net Income4 14,150 12,191 14,6
Slide 7: India: Focus on outperforming market growth
India: Focus on outperforming market growth Brief Overview India businessBrief grew 13.9% Overview 1 YoY Leveraging Chronic Leadership India Sales (INR mn) #2 #3 #3 Rank Rank Rank 23,796 Respiratory2 Cardiac2 Diabetes Care2 20,894 20,777 20,387 19,082 • Chronic growth 21.5% in Q1 (vs IPM growth of 1
Slide 8: India: Focus on outperforming market growth
India: Focus on outperforming market growth IRF poised to outperform IPM by 1.2-1.3x with key drivers in place Enabling end to end healthcare ecosystem & access for the patient Enhancing penetration and reach • CHC Portfolio catering to GI, VMS, Cough/cold • Maximizing Chronic focus with ~70% share
Slide 9: United States: Sustained growth through portfolio execution
United States: Sustained growth through portfolio execution Leadership: Brief Overview ~5.0% Gx TRx volume Continued momentum led by investments in Brief Overview Consistent Sales trajectory3 complex Gx & 505(b)(2)s share in U.S1 Sales in US$ Mn 30% YoY (1%) QoQ • Plans to file 15+ ANDAs in FY27 #3
Slide 10: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and biosimilars Achieve Best-in-Class Quality Substantial Capabilities to become CGx powerhouse Recent Track Record • Inhalation: Global presence with end-to-end capabilities of MDIs, Successful outcomes in last 12 months DPIs, Soft-Mist I
Slide 11: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D1 (INR mn) Capex1 (INR mn) Net Debt to Equity 4,500 15.0% 6,500 5,898 6,077 15.0% 4,000 13.0% 5,222 5,352 13.0% 3,474 5,500 4,975 3,500 3,052 11.0% 4,500 11.0% 3,000 2,786 0.35 9.0% 9.0% 2,500 3,500 2,086 2,007 7.0% 8.1% 7.6% 8.0% 7.0% 2,000 2,500 7.5% 7.4%
Slide 12: P&L Highlights Q1 FY27
P&L Highlights Q1 FY27 Particulars Q1’FY27 % of Sales Q1’FY26 % of Sales YoY Growth Q4’FY26 % of Sales QoQ Growth Net Sales 82,172 100.0% 61,638 100.0% 33.3% 73,919 100.0% 11.2% Other operating 597 0.7% 1,045 1.7% (42.9%) 828 1.1% (27.9%) income Total revenue 82,769 100.7% 62,683 101.7% 32.0% 74,747
Slide 13: Lupin at a Glance
LUPIN Lupin at a Glance
Slide 14: Lupin Today
Lupin Today Global Presence Local Leadership Geographically Diverse Growing Sustainability India United States 14th $3.2 Bn 3rd Largest In the US (by prescriptions2) 81,140 30% 116,783 42% 91/100 8th India Pharma Market Rank (by sales3) Largest Generic Annual sales Company in FY266 4th Largest Austr
Slide 15: Catalyzing Treatments that transform hope into healing
Catalyzing Treatments that transform hope into healing United States Other Developed India Other Emerging API Markets Markets Driving operating leverage Delivering above-market Global reach and scale Substantial scale Evolving portfolio and in Portfolio, Capex and growth. positions us as a partner a
Slide 16: Lupin's Sustainability Update
Lupin’s Sustainability Update Paving a sustainable future for Planet, People and Patients Sustainability Goal Status FY 2026 Key Highlights for Q1 FY27 Climate Change1 42% GHG Reduction by 2030 ~41% GHG Reduction Water 50% Recycling by 2030 ~45% Recycling Biodiversity 66% Sites Completed Assessment
Slide 17: Lupin ESG Framework and ESG Ratings
Lupin ESG Framework and ESG Ratings Our Purpose We catalyze treatments that transform hope into Planet People Patients healing Catalyzing Planet Action Transforming Our People Healing Patients Climate Change Diversity and Inclusion Product Launches and Quality Our ESG Framework Water Employee Volunt
Slide 18: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Lupin placed among the Top 1% of companies in Pharma industry based on S&P Global CSA score for 2025. Earns a spot in Sustainability Yearbook for 3rd time in a row • Lupin Secured Global No. 1 Ranking in the Pharma Sector in S&P Global ESG Ratings and Secured No. 1 in
Slide 19: THANK YOU!
THANK YOU! Lupin.com MadeInIndia.com lupin.com REGISTERED OFFICE lupin.com x.com/LupinGlobal 3rd Floor, Kalpataru Inspire, Off Western Express x.com/LupinGlobal Highway, Santacruz (East), Mumbai - 400 055. India. linkedin.com/company/lupin/ linkedin.com/company/lupin/ Tel: + 91 22 6640 2323 facebook